Sanntidsoppdatering for Green Cross Corporation [006280.KS]

Green Cross Corporation, a biopharmaceutical company, develops drugs and vaccines in South Korea. The company provides plasma derivatives, including albumin, immunoglobulin, and antithrombin; and vaccines for hepatitis-B, Hantavirus hemorrhagic fever, influenza, flu, and varicella. It also offers prescription drugs for the bleeding symptom control and hemostasis for persons with hemophilia A; prevention and treatment of bleeding episodes induced by hemophilia A and post-operative treatment; and treatment of neutropenia, hunter syndrome, and liver cancer, as well as treatment of anti-inflammation, pain relief, and osteoarthritis. In addition, the company provides over the counter drugs. It also exports its products to approximately 50 countries. The company has a licensing and collaboration agreement with Tottori University for development of GM1 gangliosidosis chaperone therapy. The company was formerly known as Sudo Microorganism Medical Supplies Company and changed its name to Green Cross Corporation in 1971. Green Cross Corporation was founded in 1967 and is headquartered in Yongin-si, South Korea. Green Cross Corporation is a subsidiary of Green Cross Holdings Corporation.